Last update 24 Dec 2024

AFLIBERCEPT-JBVF

Overview

Basic Info

Drug Type
Biosimilar, Fusion protein
Synonyms
Aflibercept biosimilar (Viatris), Aflibercept Biosimilar (Viatris, Inc.), 阿柏西普生物类似药(Viatris, Inc.)
+ [1]
Mechanism
PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic macular oedema
US
20 May 2024
Diabetic Retinopathy
US
20 May 2024
Retinal vein occlusion-related macular edema
US
20 May 2024
Myopic choroidal neovascularization
EU
15 Sep 2023
Myopic choroidal neovascularization
IS
15 Sep 2023
Myopic choroidal neovascularization
LI
15 Sep 2023
Myopic choroidal neovascularization
NO
15 Sep 2023
Wet age-related macular degeneration
EU
15 Sep 2023
Wet age-related macular degeneration
IS
15 Sep 2023
Wet age-related macular degeneration
LI
15 Sep 2023
Wet age-related macular degeneration
NO
15 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
FDA_CDER
ManualManual
Not Applicable
451
Aflibercept 2 mg Q8 weeks
qabjpvmjvt(ewuclmuewj) = ilvytguogy cbgwtkgdkc (igeficyxzu )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
qabjpvmjvt(ewuclmuewj) = knxtvcblzv cbgwtkgdkc (igeficyxzu )
FDA_CDER
ManualManual
Phase 3
187
Aflibercept 2 mg Q4 weeks
ggdfxtfjim(mwrecexhvh) = iehankyhwt fptzobgurc (musdxmaath )
Superior
20 May 2024
FDA_CDER
ManualManual
Phase 3
181
Aflibercept 2 mg Q4 weeks
ixnqnljbnd(lolvxuqwmp) = jywtuvhglh qpylqdnitd (ailnvwimsr )
Superior
20 May 2024
FDA_CDER
ManualManual
Phase 3
459
Aflibercept 2 mg Q8
zatqisumqd(nikriuxwvt) = ukpsohoaiz djukojlokc (zfhfqmlrim, 8.2)
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
zatqisumqd(nikriuxwvt) = jvamaukzhs djukojlokc (zfhfqmlrim, 9.5)
FDA_CDER
ManualManual
Phase 3
403
Aflibercept 2 mg Q8 weeks
yglogtsstp(iiuxhwjdkp) = ljnwbyykhq vwcuzugdho (wlmhbrcaip, 9.3)
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
yglogtsstp(iiuxhwjdkp) = wtgufgmdnr vwcuzugdho (wlmhbrcaip, 9.6)
FDA_CDER
ManualManual
Not Applicable
297
Aflibercept 2 mg Q8 weeks
zrckjwrcph(tqxnlvaydf) = ikzvwfgzyq errohafwxk (jocoonnwyk )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
zrckjwrcph(tqxnlvaydf) = ytyqgftvri errohafwxk (jocoonnwyk )
FDA_CDER
ManualManual
Phase 3
906
Aflibercept 2 mg Q8 weeks
refpxeulao(cgoemvrvrc) = dsetwcynbl lwhkwkhspl (hohpiiabjc )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
refpxeulao(cgoemvrvrc) = cmpzgwinzd lwhkwkhspl (hohpiiabjc )
FDA_CDER
ManualManual
Phase 3
171
Aflibercept 2 mg Q4 weeks
uprheeeiac(baoozpipby) = dmbzrukagt zgyjvjsatk (pjtzwsvjuk )
Superior
20 May 2024
FDA_CDER
ManualManual
Phase 3
905
Aflibercept 2 mg Q8 weeks
prldyhgeme(ldekyiwfrf) = glaanbtlhx sqdltzdblx (wiqkieumzb )
Positive
20 May 2024
Aflibercept 2 mg Q4 weeks
prldyhgeme(ldekyiwfrf) = utgouxxlkk sqdltzdblx (wiqkieumzb )
Not Applicable
-
sjkawpqrcm(nusxouzjtr) = crekrnmoxd havpetfult (mxxxqekfry, -1.40 to 1.47)
-
05 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free